How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

542 results for


Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

341. What is the evidence for neuropathic pain medication in postherpatic neuralgia? Is there any evidence for gabapentin v amitriptyline?

with acute herpes zoster may continue to have pain for 5 years or more. Oral antiviral agents (aciclovir, famciclovir, valaciclovir and netivudine), taken during acute herpes zoster infection, may reduce the duration of postherpetic neuralgia compared with placebo. We don’t know whether topical antiviral drugs, tricyclic antidepressants or corticosteroids taken during an acute attack reduce the risks of postherpetic neuralgia, as few good quality studies have been found. Corticosteroids may cause

2007 TRIP Answers

342. Is there any evidence for prescribing antivirals in any patient with shingles, independent of location or age?

into these categories, to help reduce the severity or duration of the rash. Antivirals should be started within 72 hours of the rash onset. - Aciclovir is much less expensive than other antivirals, but is taken five times a day. - If compliance is an issue: consider valaciclovir (taken three times a day) or famciclovir (taken once a day or three times a day).” Reference 1) Answered 20 May 2008 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2008 TRIP Answers

343. Does the administration of oral steroid along with Aciclovir for herpes zoster reduce the incidence of post-herpetic neuralgia?

neuralgia [Alper and Lewis, 2000; Wareham, 2004].” Clinical Evidence has a more up to date (2006) chapter on postherpetic neuralgia [2]. This includes the section “What are the effects of interventions during an acute attack of herpes zoster aimed at preventing postherpetic neuralgia?” which reports the following: “ Likely to be beneficial Oral antiviral agents (aciclovir, famciclovir, valaciclovir, netivudine) Unknown effectiveness Dressings Topical antiviral agents (idoxuridine) for pain at 6 months

2007 TRIP Answers

344. What evidence is there for using prophylactic aciclovir for recurrent herpes simplex, on the face or gentials?

suppressive treatment. Intermittent suppressive therapy may be an option for some people, for example to ensure they do not have an attack during a specified period, for example a holiday. Aciclovir 400 mg twice a day, aciclovir 200 mg four times day, valaciclovir 250 mg twice daily, or valaciclovir 500 mg daily are equally effective for suppression of genital herpes. Safety and resistance data on long-term aciclovir therapy extends to 15 years. Famciclovir 250 mg twice a day is also effective

2004 TRIP Answers

345. Is there any preventative action or treatment which helps with recurrent facial cold sores? Are any investigations indicated?

with placebo (P v 21/102 [21%] with placebo; P = 0.92). The third RCT (20 people with recurrent herpes labialis) found that aciclovir (400 mg twice daily for 4 months) led to 53% fewer clinical recurrences than placebo (P = 0.05). The fourth RCT (248 adults with a history of sun-induced recurrent herpes labialis) compared three different dosages of famciclovir (125, 250, and 500 mg) versus placebo. Treatment was given three times daily for 5 days, beginning 48 hours after exposure to artificial ultraviolet (...) light. The RCT found no significant difference in the number of lesions among the four groups (number of lesions reported as non-significant; P value not reported). However, it found that increasing the dose of famciclovir significantly reduced the size and duration of lesions, in a dose–response relation. Compared with placebo, the 500 mg dose, but not the other doses, significantly reduced the mean size of lesions and reduced the mean time to healing by 2 days (mean size of lesions: P = 0.04; mean

2006 TRIP Answers

346. Should fit non-immunocompromised adults with chickenpox have anti-viral Rx?

showed no important difference between aciclovir and placebo with respect to complications associated with chickenpox [Klassen et al, 2004]. We found no studies that assess the efficacy of famciclovir or valaciclovir for the treatment of chickenpox.” References 1) PRODIGY. Chickenpox. 2004 ( ) Answered 5 April 2006 Follow us: © 2019 Trip Database Ltd. company number 04316414. Trip is proud to be made in the UK.

2006 TRIP Answers

347. Entecavir Intensification for Persistent HBV Viremia in HIV-HBV Infection

of the investigator puts the subject at potential risk from study participation or makes adherence to the study protocol unlikely. Receipt of the following drugs with anti-HBV activity within 90 days prior to study entry or anticipated receipt during the course of the study including: adefovir(ADV), telbivudine, alpha interferon, penciclovir (Denavir) (except if given for < 4 weeks), famciclovir (Famvir), diaminopurine dioxolane (DAPD), clevudine (L-FMAU), thymosin alpha 1, ganciclovir (treatment limited to < 7

2008 Clinical Trials

348. Seroprevalence of HSV-2 in HIV Infected Subjects and the Effect of Daily Valacyclovir in the Reduction of HSV-2 Recurrence and Viral Shedding

, transdermal hormonal contraceptives, IUD (intrauterine device), diaphragm or cervical cap. Willing and able to provide written informed consent, undergo clinical evaluations, and take study drug as directed Exclusion Criteria: History of symptomatic genital herpes, lesions or symptoms consistent with genital herpes, or recurrent undiagnosed symptoms consistent with genital herpes. Known history of adverse reaction to acyclovir, valacyclovir, or famciclovir. Planned open label use of acyclovir (...) , valacyclovir, ganciclovir, valganciclovir, famciclovir, cidofovir, or foscarnet for oral herpes or other herpes viral infections. Medical history of seizures Renal insufficiency, defined as serum creatinine greater than 1.5 mg/dl AST (aspartate aminotransferase) or ALT (alanine aminotransferase) over 5 times uper limit of normal History of thrombotic microangiopathy For women, pregnancy as confirmed by a urine or serum pregnancy test. Any other condition which, in the opinion of the principal investigator

2008 Clinical Trials

349. Effects of Telbivudine and Tenofovir Disproxil Fumarate on the Kinetics of Hepatitis B Virus DNA in Chronic Hepatitis B (CHB)

the preceding two years. Please refer to Appendix 3. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir. Please refer to Appendix 1. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its identifier (NCT number): NCT00804622 Locations

2008 Clinical Trials

350. Efficacy of Methylprednisolone for Hantavirus Cardiopulmonary Syndrome

pneumonia. Immunocompromised patients at risk of opportunistic infection (e.g., patients with HIV infection, underlying malignancy, or who have received chemotherapy or immunosuppressive drugs within 30 days.) Patients who have or will receive any systemic antiviral medication (other than acyclovir, famciclovir, amantadine or rimantadine), systemic corticosteroids equivalent to approximately 0.5mg/kg prednisone, or any investigational drug within 30 days before enrollment or during treatment. Any period

2005 Clinical Trials

351. A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: Male Accepts Healthy Volunteers: No Criteria Inclusion Criteria: HIV seropositive and HSV-2 seropositive MSM (men having sex with men) 18 years old or older Exclusion Criteria: Known history of adverse reaction to acyclovir or valacyclovir Planned open label use of acyclovir, valacyclovir or famciclovir Contacts and Locations Go to Information from the National Library of Medicine To learn more about

2005 Clinical Trials

352. G207 Followed by Radiation Therapy in Malignant Glioma

in chemotherapy, cytotoxic therapy, immunotherapy or gene therapy protocol within 6 weeks of enrolment Required steroid increase within 2 weeks prior to injection HIV seropositive Concurrent therapy with any drug active against herpes simplex virus (HSV) (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, foscavir, cidofovir) Active oral or genital herpes lesion Any contraindication for undergoing MRI such as pacemakers, infusion pumps, ferromagnetic aneurysm clips, metal prostheses, etc

2005 Clinical Trials

353. A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients

or suspected to be immunocompromised (e.g., subjects receiving immunosuppressive therapy or chemotherapy for malignancy, or are seropositive for HIV). Received an investigational drug in the 30 days prior to the study. Receiving systemic antiviral or immunomodulatory treatments. Must not have received systemic antiviral treatments (e.g., valaciclovir, Famvir (famciclovir), acyclovir, lysine) within 3 days of starting study drug or immunomodulatory treatments in the 30 days before starting study drug (...) . Clinically significant impaired renal function as defined by a creatinine clearance <30 ml/min, calculated using the Cockcroft-Gault formula. Clinically significant impaired hepatic function defined as an ALT (alanine transaminase) level > 5 times the normal upper limit. Subjects with active liver disease. Known to be hypersensitive to acyclovir, famciclovir, ganciclovir or any component of valaciclovir formulations. Known resistance to acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir

2005 Clinical Trials

354. A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

-month study. Laboratory confirmation of genital herpes (a positive Herpes Simplex Virus-2 antibody test). 3 or more outbreaks of genital herpes in the previous 12 months if not on genital herpes medicines currently. 3 or more outbreaks of genital herpes per year in the period prior to beginning of treatment for chronic genital herpes. Exclusion Criteria: Kidney diseases. Liver diseases. Known allergic reactions to VALTREX (valaciclovir), ZOVIRAX (acyclovir), FAMVIR (famciclovir), or CYTOVENE

2004 Clinical Trials

355. To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)

that a barrier method of contraception be used (i.e. condom with spermicide or diaphragm with spermicide) by patients of childbearing potential (men and women) regardless of whether a hormonal agent also is used as a method of contraception; Patient is co infected with hepatitis C virus (HCV), HIV. Patients will be tested for antibodies to HCV & HIV in the Screening assessments;Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir; Patient is currently

2007 Clinical Trials

356. Prospective Exploratory Study to Evaluate the Safety and Efficacy of Telbivudine in the Fifth Year of Treatment in Chinese Patients With Compensated Chronic Hepatitis B

participating in this study. All other treatments for hepatitis B, including commercially available treatments indicated for conditions other than chronic hepatitis B that are being investigated to treat or may have activity against HBV (e.g., ribavirin, famciclovir, ganciclovir, etc.) Prolonged use of systemic acyclovir or famciclovir defined as episodic treatment with these agents for periods exceeding 10 days every 3 months, or chronic suppressive therapy. Systemic immunomodulators of any type. Systemic

2008 Clinical Trials

357. ZOSTAVAX™ Safety Study in Subjects ≥ 60 Years of Age (V211-020)

immunodeficiency virus (HIV) infection, organ or bone marrow transplantation, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, or generalized malignancy. Subjects with a history of cancer who are not on active treatment and are not thought to have a weakened immune system at the time of enrollment will be eligible Any active use of non-topical antiviral therapy including but not limited to acyclovir, famciclovir, valacyclovir, ganciclovir, foscarnet, brivudine, and cidofovir Contacts and Locations Go

2007 Clinical Trials

358. Effects of Telbivudine and Tenofovir Disoproxil Fumarate Treatment on the Hepatitis B Virus DNA Kinetics in CHB

concurrent medical or social condition likely to preclude compliance with the schedule of evaluations in the protocol, or likely to confound the efficacy or safety observations of the study. Patient is currently abusing alcohol or illicit drugs, or has a history of alcohol abuse or illicit substance abuse within the preceding two years. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir. Other protocol-defined inclusion/exclusion criteria may

2008 Clinical Trials

359. GUD Clinical and Virologic Response to Acyclovir in HIV Negative African Women

(Focus HerpeSelect >3.4) At least one prior occurrence of GUD 18-50 years of age Exclusion Criteria: Current use, or use w/in past 7 days of acyclovir, valacyclovir, or famciclovir Prior hypersensitivity &/or allergic reaction to acyclovir Use of probenicid Current use, or use within past 28 days, of an investigational agent Currently pregnant or nursing Currently plan to become pregnant during next 3 months Any condition that will interfere with successful completion of study procedures Contacts

2008 Clinical Trials

360. A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)

a history of or clinical signs/symptoms of hepatic decompensation such as ascites, esophageal variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, hepatic hydrothorax, hepatopulmonary syndrome or spontaneous bacterial peritonitis. Patient has a medical condition that requires prolonged or frequent use of systemic acyclovir or famciclovir. History of malignancy of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or metastases

2008 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>